C hronic prostatitis (CP) is a common condition with a huge impact on the quality of life of many men. Based on a population of more than 10600 participants, a systematic review found a population-based prevalence of prostatitis symptoms of 8.2% (range 2.2-9.7%). 1 However, the condition is poorly understood, underdiagnosed and difficult to treat. As a result, there is a lack of good evidence and guidance, for primary care in particular, on how to recognise the condition and carry out effective management in the community.
GUIDELINE DEVELOPMENT
The Prostatitis Expert Reference Group (PERG) was convened in 2013 by the charity Prostate Cancer UK, to undertake a review of the literature and produce a guideline suitable particularly for non-specialist use. Members of PERG were selected from a network of clinical experts in the urology field across a broad range of disciplines, including primary care, urology (medical and specialist nursing), pain, physiotherapy and psychology, from across England. In addition, PERG included a technical team of representatives from Prostate Cancer UK and Hayward Medical Communications, who had a background in communication, policy development and evidence research.
The guideline 2 covers only symptomatic, chronic forms of prostatitis; thus, the patient populations under the National Institutes of Health (NIH) classification categories I (acute bacterial prostatitis) and IV (asymptomatic inflammatory prostatitis) 3 were not considered during guideline development. Due to the limited number of published randomised controlled trials (RCTs) in CP/chronic pelvic pain syndrome (CPPS), the PERG concluded that the guidelines would benefit from a supporting web-based Delphi consensus panel. This is an anonymous group technique, delivered via the online Survey Monkey platform, designed to gather individual opinions from experts in areas where high quality, published evidence is currently lacking, and transform these into a group consensus. 4 Most men with CP do not have an ongoing infection, and only a small minority can be categorised as having chronic bacterial LUTS, lower urinary tract symptoms; NSAIDs, non-steroidal anti-inflammatory drugs; PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalised Anxiety Disorder-7; MDT, multidisciplinary team; BSSM, British Society for Sexual Medicine. 5 The UPOINT scale may be used particularly by clinicians with an interest in CP/CPPS or in a research setting. Its value is to provide a symptomdirected focus to treatment and it has demonstrated the value of multimodal therapy.
The investigations and physical examinations that should be considered during clinical assessment, including whether they are considered as a core or optional part of the assessment and in which setting they are typically completed (eg non-specialist versus specialist), are summarised in Table 1 (page 13) .
DIAGNOSIS
To establish a diagnosis of CBP or CP/CPPS, the patient should, by definition, have a history of persistent or recurrent symptoms, and the absence of other urogenital pathology (eg active urethritis, urogenital cancer, urinary tract disease), for a minimum of 3 out of the past 6 months. 6 However, some men have fluctuating symptoms and, in practice, the diagnosis is often suspected after a shorter duration of symptoms.
A definitive diagnosis of CBP relies on the presence of (typically recurrent) urinary tract infection and isolation of an aetiologically recognised organism from prostatic fluid or urine. However, in many cases, patients respond to antibiotic intervention in the absence of a confirmed infection -in such cases, a CBP diagnosis can be suspected but is not certain, since the response may be due to the anti-inflammatory or antineuropathic effect of the antimicrobial agent. There is no gold standard for a definitive diagnosis of CP/CPPS; instead, it is typically based on a patient history, symptoms and the exclusion of other causes (eg non-demonstrable infection and other urogenital pathology).
TREATMENT STRATEGIES
PERG undertook a review of the literature for all treatments for CBP and CP/CPPS. There are many areas where the evidence base is weak, and the Delphi consensus process was used to try to ascertain expert opinion. The guideline recommends an initial course of an antibiotic for all patients, with simple analgesia/anti-inflammatories, but at an early stage recommends a symptom-based approach to treatment (Figure 1 ). Where neuropathic pain is suspected, early use of antineuropathic agents such as tricyclic antidepressants or gabapentin should be considered ( Table 2) .
REFERRAL
Early referral to specialist services is suggested for men with severe symptoms or where there is diagnostic uncertainty. This may be to a urologist with an interest in CP/CPPS, a pain physician or sexual health clinic, depending on local expertise in this condition.
When a patient's pain is severe and refractory to initial treatment, or when the pain is significantly impairing the patient's lifestyle and ability to participate in daily activities, it is worth referring him to a specialist pain service. Specialist treatments provided may include: With any pain condition, delay to recovery can lead to chronicity, a reduction in physical function and the development of psychosocial sequelae. Thus, early referral to a specialist pain service for patients who are not improving, despite appropriate treatment, is recommended.
Studies have shown that the symptoms of CBP and CP/CPPS may be the result of physical dysfunction, such as abnormal pelvic muscle spasm and muscle tenderness. Thus, the use of physical techniques, in the form of specialist physiotherapy, may have a role in ameliorating symptoms of CBP and CP/CPPS. Treatment options may include pelvic floor re-education, local pelvic floor relaxation, biofeedback, relaxation and mindfulness, trigger point or myofascial release, bladder retraining, TENS or acupuncture.
While it is recognised that psychosocial symptoms may be part of CBP and CP/CPPS, no evidence from RCTs or comparative studies is available to support the use of psychological treatment or cognitive behavioural therapy (CBT). The Delphi process was used to reach a consensus about what is considered to be best practice with respect to CBT and psychotherapy. The conclusion of the panel was that psychosocial symptoms should be assessed both in the early and late stages of CBP and CP/CPPS. If there is a significant suspicion of psychological factors contributing to a patient's condition, these should be screened for. CBT should be considered in conjunction with other treatments in patients with later-stage CBP and CP/CPPS, as the panel felt that it may improve pain and quality of life.
Over the years, urologists have used a number of surgical techniques and prostatic massage to provide relief from the symptoms of CP/CPPS. However, the PERG review concluded that there is insufficient evidence to warrant recommending surgical techniques, including radical prostatectomy, transurethral resection of the prostate, transrectal high-intensity focused ultrasound, or prostatic massage for the treatment of CBP or CP/CPPS, except in the context of a clinical trial setting. In particular, the use of repetitive outpatient prostatic massage or prostatic massage under general anaesthetic as treatment options in refractory patients was put forward to the Delphi panel for comment and response; however, no consensus was reached on their potential use.
CONCLUSION
Treatment of CP is difficult, but not impossible. When the condition is suspected, it is vital that time is spent discussing the diagnosis with the patient and understanding his individual symptom patterns and concerns, as this will be important in targeting appropriate therapies.
The PERG guideline provides a framework for initial assessment and management in a non-specialist setting. Box 2 illustrates the priorities identified by the group for implementation in clinical practice.
Declaration of interests: none declared. J on Rees and Andrew Doble are to be congratulated on producing an excellent report. Prostatitis is a very common affliction of younger and middle-aged men. In the USA, prostatitis is diagnosed in 8% of all visits to a urologist and 1% of all primary care physician visits. The term prostatitis refers, in its strictest sense, to histological inflammation of the tissue of the prostate gland. Like all forms of inflammation, it can be associated with an appropriate response of the body to an infection, but it very frequently occurs in the absence of infection.
The cause of this sometimes very bothersome disorder is still mysterious. Many years ago Roger Kirby performed a small study when a junior doctor at St Thomas's Hospital. 1 We proved by using instillations of Indian ink into the bladder that voided urine was capable of refluxing backwards into the prostatic ducts. We postulated at that stage that this phenomenon might initiate a chronic inflammatory process within the prostate.
Much more recently we reported a case of a family practitioner whose chronic prostatitis responded dramatically to treatment with a phoshodiesterase type 5 (PDE5) inhibitor. 2 The longer acting PDE5 inhibitor tadalafil has been proven in randomised controlled trials to be effective in the treatment of erectile dysfunction. 3 In addition, it has been shown to have a beneficial impact on LUTS in men with BPH, who also often suffer from concomitant difficulties with erections. 4 Recently a meta-analysis of 17 trials has confirmed that tadalafil also significantly improves ejaculatory function. 5 In addition to the symptom of pelvic pain, men with chronic abacterial prostatitis/prostatodynia also frequently complain of associated LUTS and ejaculatory discomfort. Consequently treatment with tadalafil at a dose of 5mg/day for a period of time seems logical. It could be surmised that many of its beneficial effects might stem from an improvement of blood flow to pelvic organs as a consequence of its antiinflammatory and vasodilatory activity, as well as a relaxant effect on smooth muscle, as has been previously suggested in the case of LUTS by Andersson et al. 6 Clearly a randomised controlled trial will be required to test this hypothesis, but in the absence of a proven infection, a trial of PDE5 inhibitor treatment would seem considerably more logical than prolonged antibiotic treatment, which is only likely to increase the risks of antibiotic resistance.
